Pharmaceuticals stocks
제약
What are Pharmaceuticals stocks in Korea?
The Pharmaceuticals theme on jonbur groups 110 Korean stocks listed on KOSPI and KOSDAQ, worth ₩169T in total. On Oct 29, 2026 the group moved down 0.50% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 110
- Total market value
- ₩169T
- Day's move
- −0.50%
- As of
- Oct 29, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Yuhan | Oct 28Preliminary | ₩586B | +2.8% | ₩35B | +57.8% | −48.0% | 5.9%3.9% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| ST Pharm | Oct 27Preliminary | ₩98B | +19.1% | ₩16B | +6.6% | −14.3% | 16.1%18.0% |
| Boryung | Oct 22Preliminary | ₩314B | +12.3% | ₩25B | −13.4% | +7.1% | 8.1%10.5% |
| Bukwang Pharmaceutical IND | Oct 23Preliminary | ₩58B | +21.2% | ₩2.2B | +120.7% | +53.3% | 3.7%2.0% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| Whanin Pharm | Oct 29Preliminary | ₩72B | +8.9% | ₩7.5B | +111.8% | −4.6% | 10.5%5.4% |
| Kyongbo Pharmaceutical | Oct 30Preliminary | ₩66B | −1.2% | ₩100M | −78.9% | −89.3% | 0.2%0.7% |
| Hyundai Pharmaceutical | Expected around Oct 15 | ||||||
| Samsung Biologics | Expected around Oct 28 | ||||||
| Hanmi Science | Expected around Oct 29 | ||||||
| HK inno.N | Expected around Oct 29 | ||||||
| Dong-A Pharmaceutical | Expected around Oct 29 | ||||||
| Korea United Pharm | Expected around Oct 30 | ||||||
| Handok | Expected around Oct 30 | ||||||
| Myungin Pharm | Expected around Oct 31 | ||||||
| Samik Pharm | Expected around Oct 31 | ||||||
| Chong Kun Dang Pharmaceutical | Expected around Nov 3 | ||||||
| JW Pharmaceutical | Expected around Nov 3 | ||||||
| GC WellBeing | Expected around Nov 3 | ||||||
| SK Chemicals | Expected around Nov 5 | ||||||
| Yungjin Pharm | Expected around Nov 5 | ||||||
| JW Lifescience | Expected around Nov 5 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| Ildong Holdings | Expected around Nov 6 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| Huons | Expected around Nov 10 | ||||||
| Vivozon Pharmaceutical | Expected around Nov 10 | ||||||
| GL Pharm Tech | Expected around Nov 10 | ||||||
| Samyang NC Chem | Expected around Nov 13 | ||||||
| Ilyang Pharmaceutical | Expected around Nov 13 | ||||||
| Kukjeon | Expected around Nov 13 | ||||||
| Sam-A Pharm | Expected around Nov 13 | ||||||
| Shinil Pharmaceutical | Expected around Nov 13 | ||||||
| Daehan Nupharm | Expected around Nov 13 | ||||||
| CMG Pharmaceutical | Expected around Nov 13 | ||||||
| Hwail Pharm | Expected around Nov 13 | ||||||
| Poongjeon Pharmacy | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| HLB | Expected around Nov 14 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| D&D Pharmatech | Expected around Nov 14 | ||||||
| DongKook Pharmaceutical | Expected around Nov 14 | ||||||
| Daewoong | Expected around Nov 14 | ||||||
| Komipharm International | Expected around Nov 14 | ||||||
| Shinpoong Pharmaceutical | Expected around Nov 14 | ||||||
| GC | Expected around Nov 14 | ||||||
| T&L | Expected around Nov 14 | ||||||
| Kwangdong Pharmaceutical | Expected around Nov 14 | ||||||
| Huons Global | Expected around Nov 14 | ||||||
| Samjin Pharmaceutical | Expected around Nov 14 | ||||||
| Humedix | Expected around Nov 14 | ||||||
| Ilsung IS | Expected around Nov 14 | ||||||
| Union Korea Pharm | Expected around Nov 14 | ||||||
| Chongkundang Holdings | Expected around Nov 14 | ||||||
| Dongsung Chemical | Expected around Nov 14 | ||||||
| DAE HWA Pharm | Expected around Nov 14 | ||||||
| Reyon Pharmaceutical | Expected around Nov 14 | ||||||
| Samil Pharmaceutical | Expected around Nov 14 | ||||||
| Kyungdong Pharm | Expected around Nov 14 | ||||||
| Daehan Pharmaceutical | Expected around Nov 14 | ||||||
| Hana Pharm | Expected around Nov 14 | ||||||
| Dongwha Pharm | Expected around Nov 14 | ||||||
| Jeil Pharmaceutical | Expected around Nov 14 | ||||||
| Ahn-Gook Pharmaceutical | Expected around Nov 14 | ||||||
| Dongsung Pharmaceutical | Expected around Nov 14 | ||||||
| Samsung Pharmaceutical | Expected around Nov 14 | ||||||
| Jeil Pharma Holdings | Expected around Nov 14 | ||||||
| Optus Pharmaceutical | Expected around Nov 14 | ||||||
| High Tech Pharm | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| DongKoo Bio & Pharma | Expected around Nov 14 | ||||||
| Korea Pharma | Expected around Nov 14 | ||||||
| Icure Pharmaceutical Incorporation | Expected around Nov 14 | ||||||
| Withus Pharmaceutical | Expected around Nov 14 | ||||||
| Polaris AI Pharma | Expected around Nov 14 | ||||||
| Daebonglsco | Expected around Nov 14 | ||||||
| SY Dong-A | Expected around Nov 14 | ||||||
| Kukje Pharma | Expected around Nov 14 | ||||||
| Sinsin Pharmaceutical | Expected around Nov 14 | ||||||
| Yuyu Pharma | Expected around Nov 14 | ||||||
| BL Pharmtech | Expected around Nov 14 | ||||||
| JIN Yang Pharmaceutical | Expected around Nov 14 | ||||||
| CJ Bioscience | Expected around Nov 14 | ||||||
| Myungmoon Pharm | Expected around Nov 14 | ||||||
| Kyung NAM Pharm | Expected around Nov 14 | ||||||
| Korean Drug | Expected around Nov 14 | ||||||
| Bcworldpharm | Expected around Nov 14 | ||||||
| Korea Arlico Pharm | Expected around Nov 14 | ||||||
| Tdspharm | Expected around Nov 14 | ||||||
| Wooyang | Expected around Nov 14 | ||||||
| Seoul Pharma | Expected around Nov 14 | ||||||
| Telcon RF Pharmaceutical | Expected around Nov 14 | ||||||
| Jeonjinbio | Expected around Nov 14 | ||||||
| ChoA Pharmaceutical | Expected around Nov 14 | ||||||
| Kmpharmaceutical | Expected around Nov 14 | ||||||
| HEM Pharma | Expected around Nov 28 | ||||||
| Daewon Pharmaceutical | Not yet | ||||||
| Pharmaresearch Bio | Not yet | ||||||
| Imgt | Not yet | ||||||
| BASKHANBIOPharma | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 29, 2026- Above 20-day average
- 7.7%
- Above 60-day average
- 13.5%
- RSI above 70
- 0%
- RSI below 30
- 19.2%
- 52-week highs
- 0
- 52-week lows
- 14
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
Across 104 Pharmaceuticals members, breadth is very weak: only 7.7% trade above their 20-day average and 13.5% above their 60-day average. No member is at a 52-week high, while 14 sit at 52-week lows, and the RSI extreme reading shows 19.2 on the oversold side with none overbought. The equal-weighted member index is below its cloud, with a 32.7 RSI and bearish short- and medium-term gauges.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 22, 202675Boryung: ₩86bn of bonds due in the next 6 months vs ₩50bn cash₩86bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.Boryung
- MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
Creators talking about this
Pharmaceuticals
−2.98%제약
The pharmaceuticals theme in Korea covers companies that develop, manufacture, and sell prescription drugs, generic medicines, and over-the-counter products, along with some firms focused on contract drug manufacturing and biosimilars. Korean investors often group these companies together because they share regulatory frameworks, drug approval processes, and sensitivity to healthcare policy such as national insurance pricing decisions. The theme is also closely watched for research pipeline news, export deals, and clinical trial results.
110 companies · 15 up · 6 flat · 89 down
- Traded value
- ₩470B
- Value vs 20-day average
- 0.76×
- Top gainer
- Poongjeon Pharmacy +7.95%
- Largest company
- Samsung Biologics ₩63T
Companies in this theme
| Company | Price | Weekly | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,366,000 | +0.37% | ₩58B | ₩63T | 6.88% |
Celltrion068270 · KOSPI | ₩189,300 | −2.57% | ₩71B | ₩44T | 7.28% |
Yuhan000100 · KOSPI | ₩74,700 | −11.07% | ₩24B | ₩5.5T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩388,500 | +4.86% | ₩63B | ₩5T | 9.61% |
Hanmi Science008930 · KOSPI | ₩42,200 | −1.63% | ₩11B | ₩2.9T | 6.27% |
ST Pharm237690 · KOSDAQ | ₩74,000 | −17.59% | ₩9.1B | ₩1.5T | 5.77% |
Daewoong Pharma069620 · KOSPI | ₩101,500 | −1.36% | ₩1.7B | ₩1.2T | 10.30% |
HK inno.N195940 · KOSDAQ | ₩34,650 | +1.61% | ₩3.4B | ₩982B | 5.03% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩62,500 | −4.14% | ₩703M | ₩863B | 6.34% |
SK Chemicals285130 · KOSPI | ₩41,550 | +0.85% | ₩2.5B | ₩719B | 8.61% |
Dong-A Pharmaceutical000640 · KOSPI | ₩86,300 | −4.85% | ₩763M | ₩581B | 9.45% |
GC005250 · KOSPI | ₩9,120 | −3.49% | ₩515M | ₩429B | 5.94% |
Source: KRX statistical information